Blackhill Capital Inc. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Blackhill Capital Inc. lowered its stake in Pfizer Inc. (NYSE:PFEFree Report) by 14.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 275,101 shares of the biopharmaceutical company’s stock after selling 45,200 shares during the period. Pfizer makes up approximately 0.6% of Blackhill Capital Inc.’s investment portfolio, making the stock its 17th biggest position. Blackhill Capital Inc.’s holdings in Pfizer were worth $7,920,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC raised its position in Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $255,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Pfizer during the 4th quarter worth about $16,166,000. Finally, KLCM Advisors Inc. grew its stake in Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.7 %

Shares of PFE stock traded up $0.48 on Friday, hitting $28.68. 78,241,670 shares of the stock traded hands, compared to its average volume of 42,258,051. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The firm’s 50-day moving average price is $27.32 and its two-hundred day moving average price is $27.91. The stock has a market capitalization of $162.52 billion, a PE ratio of -477.42, a PEG ratio of 1.09 and a beta of 0.63.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.86%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $35.86.

Get Our Latest Report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.